| Listados nuevos | Listado del poste | ¡Alarma de la subasta! Las liquidaciones en marcha/el equipo nuevo y usado/ahora hacen una oferta - todo tasado para moverse |
Other Headlines
Have News for Us?
Submit your news on the industry, people, or companies.
Forward to a FriendMore Industry Headlines
House Passes Medicare Physician Payment Reform Act Advocacy groups applaud passage of bill that would permanently repeal and replace SGR.
Aural Trumps Oral for Ear Treatment A novel microfluidic drug delivery system makes it possible to reach parts of the body poorly served by oral and injectable medications.
Scientists Find Unusual Immune System Activity in Brains of Schizophrenics The "germ theory" of schizophrenia got a mild boost this week as scientists discover that recently afflicted schizophrenics show higher levels of inflammatory proteins in the brain.
Clinical PET-MRI Moves Closer to Reality Thanks to a European grant for the HyperIMAGE project, a consortium of scientists across Europe have worked with Philips to develop a proof-of-concept, pre-clinical combined MR-PET scanner that could one day lead to improved radiation therapy and cardiology treatments.
Senate Health Care Reform Bill Unveiled Legislation may go to cloture vote this weekend. Read the details.
RSNA 2009 Preview This year's RSNA should provide a very interesting look at the effects of the economy on the major OEMs. As always, vendors are whipping up the hoopla, and inside this story are great previews of what's being debuted. But DOTmed reporters will also be there to get the real buzz. Look for video interviews in our Online News direct from the show.
Interview With Fred Robertson, President & CEO of TomoTherapy TomoTherapy president and CEO Fred Robertson talks with DOTmed about his perspective on ASTRO's 2009 annual meeting, changes in the radiation oncology industry and two important TomoTherapy product launches that occurred at the show. Watch the HD video.
Pen-Sized Microscope Aims for Precise Brain Surgeries A confocal microscope picking up brain-safe fluorescent dyes could result in more accurate and streamlined surgeries to remove tumors from the brain.
Health Care Reform Round-Up: CBO Pegs Senate Bill at $849 Billion The numbers are in on the Senate's version of reform. Also read about the wide-ranging impact that the legislation would have.
U.S. Preventive Services Task Force Has Stunning New Guidelines on Mammography Agency recommends no routine screening for women 40-49, no self-examination. Read the details.
magnetic pulse may be able
to relieve migraine pain
Magnetic Stimulation Blocks Migraine Pain
The noninvasive device delivers a therapy known as transcranial magnetic stimulation, or TMS. It works by sparking a magnetic pulse that, when held against a person's head, creates an electric current among the nerves cells of the brain. The TMS device disrupts migraines in the "aura" phase, before they trigger pain.
Migraine sufferers experiencing auras often describe seeing showers of shooting stars, zigzagging lines and flashing lights, and experiencing loss of vision, weakness, tingling or confusion. This is followed by intense throbbing head pain, nausea and vomiting. One in eight Americans suffers from migraines and only 50 to 60 percent of patients respond to individual treatments.
Dr. Yousef Mohammad, of The Ohio State University in Columbus, reported the findings at the annual meeting of the American Headache Society in Boston. In the study, researchers recruited 201 patients suffering from migraine with aura, then randomly assigned them to use the TMS device or a "sham" device the investigators used for comparison. Patients were instructed to apply the device over the site of the migraine, at its onset. The researchers found that two hours after treatment, 39 percent of the TMS patients were pain-free, versus 22 percent of patients using the sham device.
By interfering with the aura phase of migraine, Mohammad explained, TMS essentially interrupts the "electrical storm" that culminates in migraine pain. In some study patients, the treatment also eased migraine-related symptoms of nausea and sensitivity to light and sound.
Sunnyvale, California-based NeuraLieve, the manufacturer of the TMS device used in the study, funded the work. Mohammad serves on the company's board of directors.
A spokeswoman for Neuralieve told DOTmed News that the company is in the process of receiving FDA clearance for the product and working with physicians to fulfill prescriptions for the Neuralieve TMS Therapy System for their patients.
Lynn Shapiro contributed to this report.
Interested in Medical Industry News?
Subscribe to DOTmed's weekly news email and always be informed.
Click here, it takes just 30 seconds.
|
Please Send us your Comments. |
|
|
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2009 DOTmed.com, Inc.
ALL RIGHTS RESERVED
